This Week in European MedTech and HealthTech: 17th July 2026
NA
The European HealthTech landscape this week reflects a major shift away from casual consumer "wellness" apps and a deep pivot toward clinical deep-tech, workflow automation, and massive regulatory lobbying.
Here are the standout developments and funding rounds dominating the industry right now:
1. The Heavyweight Funding Deals
The market is favouring high-conviction, late-stage bets alongside specialised clinical devices:
Neko Health’s Massive Move: Swedish preventative health startup Neko Health (co-founded by Spotify’s Daniel Ek) secured a $700M Series C round. The company revealed it has reached 100,000 members and achieved profitability at the individual clinic level, continuing its massive expansion of AI-driven full-body scans across Europe.
CurifyLabs: Finnish personalized medicine startup CurifyLabs bagged €12M in Series A funding to further automate and scale its tailored drug manufacturing technology.
Respiro Diagnostics: The UK lung-health startup closed a £1M round to advance its innovative breath-based diagnostics for respiratory diseases.
2. Shift to Deep-Tech & Cross-Border Data Interoperability
European venture capital and government backing are aggressively targeting core clinical issues:
Azalea Vision Eyes Clinical Trials: Belgian healthtech firm Azalea Vision secured up to €7.5 million in EIC (European Innovation Council) Accelerator funding. The capital is designated to move their medical-grade smart contact lens, which functions as a non-invasive biosensing platform to track biomarkers via tears, into formal clinical trials.
Dismantling Regional Data Silos: The EIC announced the first three winners of its health data interoperability initiative, deploying €3.78 million. Moving past small-scale pilots, projects like CARDIO-HUB (elderly remote heart monitoring) are being fully deployed to allow seamless cross-border medical data sharing.
3. Regulatory Frictions: The "MDR vs. AI Act" Clash
Startups and regulatory bodies are tackling the administrative bottlenecks of dual compliance:
The Overlap Lobby: European healthtech developers are experiencing massive friction navigating the simultaneous compliance demands of the EU AI Act and the stringent Medical Device Regulations (MDR).Industry groups are actively lobbying the European Commission to streamline these overlapping boundaries, with EU Parliament projections estimating that harmonisation could save the ecosystem up to €3.3 billion annually in administrative bloat.
The UK's Fast-Track Pivot: Seizing on the mainland's regulatory logjam, the UK's MHRA has progressed its draft Medical Devices Regulations. This establishes an "International Reliance" pathway, allowing tech manufacturers with existing approvals from trusted global regulators to bypass standard British red tape and fast-track into the UK healthcare market.
4. Clinician Burnout Is Driving Software Adoption
According to recent data from the Philips Future Health Index, roughly 65% of European clinicians have actively ramped up their daily use of AI medical tech. Because healthcare workers are desperate to claw back time from administrative tasks, VC funding is highly concentrated on operational "plumbing", such as AI surgical infrastructure, automated clinical documentation, and scheduling platforms—rather than patient-facing apps.
>>>>
The European MedTech and medical device landscape is undergoing a massive, structural recalibration. The speculative "wellness app" era has completely evaporated, replaced by a heavy focus on clinical deep-tech, major regulatory overhauls, and structural legal changes.
The major shifts and updates defining European MedTech include:
1. The Legal Reality: The "AI Act Omnibus" & MDR Collision
The biggest structural news for device manufacturers centres on a massive breakthrough regarding how medical AI will be governed in Europe.
No Duplicate Audits: Following fierce lobbying from industry group MedTech Europe over the "double-regulation" nightmare, EU co-legislators have finalised the "AI Act Omnibus" framework. It dramatically reduces duplication, meaning AI-driven medical devices will not have to undergo two completely separate compliance pathways under both the AI Act and the Medical Device Regulation (MDR/IVDR). Instead, the AI Act's high-risk safety, data quality, and cybersecurity requirements will be integrated directly into the existing MDR/IVDR framework.
August 2028 Extension: Manufacturers of high-risk AI medical devices have officially been granted a major breathing-room extension to August 2028 to fully comply with high-risk obligations.
The Immediate August Catch: Do not wait on everything, though. Basic transparency rules—such as explicit disclosures for patient-facing AI chatbots and clear labeling of synthetic/AI-generated healthcare content, kick in next month (August 2026).
2. EU Pushes Back on Notified Bodies with Strict Timelines
In an effort to stop innovative medical devices from fleeing Europe for the US market due to approval bottlenecks, the European Commission has introduced aggressive new rules targeting Notified Bodies.
Implementing Regulation (EU) 2026/977 establishes uniform, capped maximum timelines for conformity assessments. For example, Notified Bodies are now bound to stricter time limits (e.g., 30 days for application reviews, 120 days for Quality Management System audits).
They must also provide fully standardised, transparent pricing quotes to manufacturers and publish their cost structures and processing duration data annually to prevent price gouging.
3. Mandatory EUDAMED Data & The Next Compliance Wave
The transition period for the first four fully functional modules of EUDAMED (the EU's centralised medical device database) ended recently.
All manufacturers, importers, and notified bodies are now under mandatory transparency compliance for devices entering the market.
New Portal Update: The European Commission announced that the playground environment for uploading crucial Summary of Safety and Clinical Performance (SSCP) data goes live this month (July 2026), ahead of the mandatory production deadline.
4. The UK's Fast-Track "International Reliance" Pathway
Capitalising on mainland Europe's historical regulatory friction, the UK's MHRA has progressed its draft Medical Devices Regulations. This explicitly establishes an "International Reliance" pathway. It allows hardware and Software-as-a-Medical-Device (SaMD) manufacturers who already hold approvals from trusted global bodies (like the US FDA) to bypass British red tape and fast-track directly into the UK market.
5. Late-Stage Capital & Deep-Tech Funding
While early-stage seed funding remains highly selective, capital is concentrating heavily on late-stage category leaders and deep-tech clinical hardware:
Alan’s Landmark Round: The French digital health and preventative insurance platform locked in a massive €480 million Series G round at a €5.5 billion valuation, making it Europe's most valuable private HealthTech entity.
Clinical Smart Lenses: Belgian MedTech firm Azalea Vision secured €7.5 million via the European Innovation Council (EIC) Accelerator. The capital will fund clinical trials for their medical-grade smart contact lens, which treats complex corneal properties and acts as a non-invasive biosensor analyzing biomarkers directly via patient tears.
Interoperability Infrastructure: Moving away from small regional "pilots," the EIC deployed millions to scale cross-border clinical data infrastructure, focusing heavily on connected hardware like CARDIO-HUB (remote cardiac monitoring for the elderly).
The Big Takeaway: Europe is actively rewriting its MedTech playbook. The extension of the AI Act deadlines coupled with strict new efficiency rules on Notified Bodies shows Brussels is finally listening to warnings about losing its innovation edge to the US and Asia.
Nelson Advisors > European MedTech and HealthTech Investment Banking
Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk
Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital
Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb
Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk
#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech
Nelson Advisors LLP
Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT
Meet Nelson Advisors @ 2026 Events
Digital Health Rewired > March 2026 > Birmingham, UK
NHS ConfedExpo > June 2026 > Manchester, UK
HLTH Europe > June 2026, Amsterdam, Netherlands
HIMSS AI in Healthcare > July 2026, New York, USA
Bits & Pretzels > September 2026, Munich, Germany
World Health Summit 2026 > October 2026, Berlin, Germany
HealthInvestor Healthcare Summit > October 2026, London, UK
HLTH USA 2026 > October 2026, USA
Barclays Health Elevate > October 2026, London, UK
Web Summit 2026 > November 2026, Lisbon, Portugal
MEDICA 2026 > November 2026, Düsseldorf, Germany
Venture Capital World Summit > December 2026 Toronto, Canada